Every year, the global pharmaceutical industry sees staggering revenues and breakthroughs. We have seen a significant transformation since the COVID-19 pandemic – global demand surged for vaccines, antivirals, and diagnostics, pushing the industry value to over $1.5 trillion by 2023. Progress in areas like mRNA and biologics moved quickly, while attention to generics grew to improve access and keep costs down and top pharmaceutical companies like Pfizer, Moderna, Johnson & Johnson, Roche, and Novartis gained prominence for their vaccine and treatment contributions. The pandemic also highlighted the importance of flexible supply chains and global collaboration across pharmaceuticals markets.
But this blog isn’t just another revenue list. This is a breakdown of how today’s pharma giants are securing their dominance — and what growth-focused brands can learn from them.
Pfizer – $63.6 Billion
Founded: 1849
Employees: 79,000+
A global leader in medicines and vaccines, Pfizer focuses on immunology, oncology, cardiology, and neurology.
Pfizer strategically spun off Upjohn to sharpen its focus on medicine, a move that allowed it to channel more resources into cutting-edge R&D, including AI initiatives in partnership with IBM Watson. Its collaboration with BioNTech on the COVID-19 vaccine not only demonstrated speed and scalability but also opened up new global markets through rapid distribution.
The takeaway: focus wins — by streamlining its portfolio, Pfizer positioned itself to move faster and scale smarter.
Johnson & Johnson – $89 Billion
Founded: 1886
Employees: 152,000+
Johnson & Johnson operates across pharma, medtech, and consumer health, with its pharmaceutical division, Janssen, driving much of its progress in new treatments.
Recently, the company made a bold move by splitting into two entities to sharpen its focus and agility. It’s also embracing digital transformation by leveraging real-world data to enhance clinical trial efficiency, while expanding its medtech capabilities through the acquisition of Abiomed (expanding into heart tech).
The takeaway: smart segmentation isn’t a setback — it’s a strategic move that enables faster, more focused growth.
AbbVie – $56.3 Billion
Founded: 2013 (spun off from Abbott)
Employees: 50,000+
AbbVie focuses on immunology, oncology, neuroscience, and virology, building a strong presence in complex disease areas.
Its acquisition of Allergan marked a bold move to diversify into aesthetics and significantly boost revenue streams. At the same time, AbbVie is integrating AI into its immunology research to speed up progress.
The takeaway: even smaller players can act like M&A leaders—smart acquisitions can open doors to new markets and quickly grow your offerings.
Merck & Co. – $64 Billion
Founded: 1891
Employees: 68,000+
Merck & Co. specializes in vaccines, oncology, and infectious diseases, with a strong emphasis on breakthrough treatments.
Its drug Keytruda continues to expand across multiple cancer indications, reinforcing Merck’s focus on oncology and vaccines.
The takeaway: specialization builds dominance—by identifying a therapeutic edge and investing deeply, Merck has positioned itself as a leader in high-impact areas.
Roche – $50.9 Billion
Founded: 1896
Employees: 102,000+
Roche operates at the intersection of pharmaceuticals and diagnostics, with a strong leadership position in oncology and personalized medicine.
The company stands out for integrating diagnostics directly into drug development, creating a smooth approach to precision medicine. By collaborating early with regulators, Roche speeds up approval timelines and ensures alignment with emerging standards.
The takeaway: combining diagnostics and therapeutics isn’t just innovative—it’s a differentiator that can future-proof your brand through cross-disciplinary partnerships.
Sanofi – $41 Billion
Founded: 1973
Employees: 100,000+
Sanofi has built a strong presence in vaccines, rare diseases, and specialty care. Recently, it’s narrowed its focus by trimming its portfolio and doubling down on areas with the most growth potential. Its partnerships with Translate Bio and Moderna have helped it push further into mRNA research and stay ahead in next-gen therapeutics.
The takeaway: companies that move early—whether it’s into mRNA, gene therapy, or AI—put themselves in a strong position to lead where the industry’s headed.
AstraZeneca – $54 Billion
Founded: 1999 (merger of Astra AB and Zeneca)
Employees: 83,000+
AstraZeneca focuses on oncology, cardiovascular, renal, respiratory diseases, and vaccines, with a robust pipeline driving consistent growth.
The company has made significant strides in emerging markets, particularly China, where it has established a strong and growing presence. Oncology products like Enhertu are also gaining traction, fueling its global performance.
The takeaway: emerging markets are both underserved and full of potential— international expansion can unlock significant growth opportunities.
Novartis – $50.3 Billion
Founded: 1996 (merger of Ciba-Geigy and Sandoz)
Employees: 108,000+
Novartis focuses on branded medicines and, until recently, also operated in generics through its Sandoz division, which it has since spun off to concentrate on its core business. That move has freed up resources for more targeted R&D, including major investments in AI and data to improve how clinical trials are run.
The takeaway: tightening your operational scope can create efficiency. Taking a closer look at what’s slowing you down might reveal exactly where to make the next move.
Bristol-Myers Squibb – $48.3 Billion
Founded: 1858 (merger in 1989)
Employees: 32,000+
Bristol-Myers Squibb operates across oncology, cardiovascular, immunoscience, and fibrosis, with a portfolio anchored by high-performing products like Revlimid and Eliquis. Its acquisition of Celgene was a bold move that has proven highly valuable, significantly boosting its pipeline and revenue.
The takeaway: sometimes, big bets lead to big returns—growth-focused pharma leaders must be willing to take calculated risks to achieve transformative gains.
GSK – $31.4 Billion
Founded: 2000 (merger of Glaxo Wellcome and SmithKline Beecham)
Employees: 70,000+
GSK has made solid progress on the regulatory front, with multiple FDA approvals helping to strengthen its presence in key therapeutic areas. It’s also expanded its work in mRNA and oncology through deeper partnerships.
The takeaway: reorganizations aren’t setbacks—they can be turning points. If your structure hasn’t changed in years, it might be worth revisiting how well it still supports where you’re headed.
The top 10 pharma companies didn’t get there by playing it safe – they moved fast, focused deep, and made bold plays. Whether through targeted M&A, global partnerships, or internal transformation, each company offers a lesson for emerging pharma brands.
You don’t have to be a giant to think like one. If you’re a growth-focused pharma company looking to scale smartly, let’s talk about how to apply these strategies to your business.
*Revenue figures are from 2024
Are you a pharmaceutical company looking to hire? Submit your vacancy and a recruitment consultant that specialises in your field will be in touch shortly.
Alternatively, Register your CV with us today to schedule a confidential discussion about your career prospects.
